Proactive Investors - Run By Investors For Investors

PreveCeutical results show key peptides derived from blue scorpion venom could reduce the aggressive nature of brain cancer

Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein that is found in the progression in certain glioblastomas
hand pointing at brain scans
Peptides may slow down the invasive spread of brain cancer cells

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) is seeing encouraging preliminary results from its research and development program that is expected to enable the company to generate key Nature Identical™ peptide therapeutics for use in treatments of brain cancer.

The health sciences company is engaged in a study that uses blue scorpion venom-derived peptides to better understand its therapeutic application in cell-based brain cancer models.

READ: PreveCeutical Medical reports successful preliminary screening of key peptides from scorpion venom research program

Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein that is found in the progression in certain glioblastomas.

Further screening highlighted the peptide’s ability to inhibit the invasion of glioblastoma cells — an important development given the invasive nature of the cells is a key factor in the aggressive spread of the disease and resulting in poor prognosis.

Research ongoing

The Vancouver-based company said in a statement that although this facet of the screening process is nearing completion, the peptide program is ongoing. According to PreveCeutical, the results have helped to progress the company towards assessing the efficacy of the lead peptides in more sophisticated glioblastoma (brain cancer) research.

PreveCeutical currently has five research and development programs underway, including gene therapy for diabetes and obesity, non-addictive analgesic peptides to replace fentanyl and the like, and soluble drug delivery program, among others.

Shares of PreveCeutical were trading at C$0.07 in Canada and US$0.05 in the US on Wednesday.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
microscope
May 01 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use